Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Leaderboard Analytics
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
Enriquez v. Nabriva Therapeutics plc et al
Case Number:
1:19-cv-04183
Court:
Nature of Suit:
Multi Party Litigation:
Class Action
Judge:
Firms
-
January 29, 2021
Nabriva Gets Initial Nod For $3M Investor Settlement
A Manhattan federal judge gave an initial nod to a $3 million settlement that would end investor claims that biopharmaceutical company Nabriva Therapeutics PLC and four of its executives misrepresented the company's prospects for getting federal approval for a new antibiotic.
-
April 28, 2020
NY Judge Dismisses Nabriva Investors' FDA Approval Suit
A Manhattan federal judge on Tuesday threw out a putative class action against Nabriva Therapeutics, ending allegations that the biopharmaceutical company misrepresented its prospects of getting federal approval for a new drug.
-
May 09, 2019
Nabriva Hit With Stock-Drop Suit Over FDA Drug Rejection
Nabriva Therapeutics misled shareholders into thinking it was about to get federal approval for a new drug when company executives knew it actually wouldn't because of substandard manufacturing conditions, according to a proposed class action filed in New York federal court.